Microalgae, a current option for the bioremediation of pharmaceuticals: a review.

In this review, research on the use of microalgae as an option for bioremediation purposes of pharmaceutical compounds is reported and discussed thoroughly. Pharmaceuticals have been detected in water bodies around the world, attracting attention towards the increasing potential risks to humans and aquatic biota. Unfortunately, pharmaceuticals have no regulatory standards for safe disposal in many countries. Despite the advances in new analytical techniques, the current wastewater treatment facilities in many countries are ineffective to remove the whole presence of pharmaceutical compounds and their metabolites. Though new methods are substantially effective, removal rates of drugs from wastewater make the cost-effectiveness ratio a not viable option. Therefore, the necessity for investigating and developing more adequate removal treatments with a higher efficiency rate and at a lower cost is mandatory. The present review highlights the algae-based removal strategies for bioremediation purposes, considering their pathway as well as the removal rate and efficiency of the microalgae species used in assays. We have critically reviewed both application of living and non-living microalgae biomass for bioremediation purposes considering the most commonly used microalgae species. In addition, the use of modified and immobilized microalgae biomass for the removal of pharmaceutical compounds from water was discussed. Furthermore, research considering various microalgal species and their potential use to detoxify organic and inorganic toxic compounds were well evaluated in the review. Further research is required to exploit the potential use of microalgae species as an option for the bioremediation of pharmaceuticals in water.

A new technique to evaluate Acidithiobacillus thiooxidans growth during a bioleaching process based on DNA quantification.

The potential of Acidithiobacillus (Thiobacillus) genus members, namely Acidithiobacillus ferrooxidans and Acidithiobacillus thiooxidans, for bioleaching purposes is known. Specifically, previous studies have shown the potential of A. thiooxidans strain DSM 26636 used in bioleaching processes to remove metals in high-metal-content matrices. All Acidithiobacillus growth-monitoring techniques available to date, including sulfate production, commonly used, present disadvantages. Thus, the current work shows a technique based on DNA quantification to evaluate the growth of A. thiooxidans DSM 26636, which is useful even in the presence of a high-metal-content residue. This proposed methodology may represent a functional complementary tool to evaluate Acidithiobacillus growth to develop biometallurgical applications.

Isolation, identification and molecular docking as cyclooxygenase (COX) inhibitors of the main constituents of Matricaria chamomilla L. extract and its synergistic interaction with diclofenac on nociception and gastric damage in rats.

Chamomile (Matricaria chamomilla L., Asteraceae) is a medicinal plant widely used as remedy for pain and gastric disorders. The association of non-steroidal anti-inflammatory drugs (NSAIDs) with medicinal plant extracts may increase its antinociceptive activity, permit the use of lower doses and limit side effects. The aim was to isolate and identify the main chemical constituents of Matricaria chamomilla ethanolic extract (MCE) as well as to explore their activity as cyclooxygenase (COX) inhibitors in silico; besides, to examine the interaction between MCE and diclofenac on nociception in the formalin test by isobolographic analysis, and to determine the level of gastric injury in rats. Three terpenoids, α-bisabolol, bisabolol oxide A, and guaiazulene, were isolated and identified by (1)H NMR. Docking simulation predicted COX inhibitory activity for those terpenoids. Diclofenac, MCE, or their combinations produced an antinociceptive effect. The sole administration of diclofenac and the highest combined dose diclofenac-MCE produced significant a gastric damage, but that effect was not seen with MCE alone. An isobologram was constructed and the derived theoretical ED35 for the antinociceptive effect was significantly different from the experimental ED35; hence, the interaction between diclofenac and MCE that mediates the antinociceptive effect is synergist. The MCE contains three major terpenoids with plausible COX inhibitory activity in silico, but α-bisabolol showed the highest affinity. Data suggest that the diclofenac-MCE combination can interact at the systemic level in a synergic manner and may have therapeutic advantages for the clinical treatment of inflammatory pain.